Evidence map›Paper›PMID 35082788›Full record

ArticleFrontiers in immunology2021

Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine.

Ramon Diez-Feijóo, Juan Jose Rodríguez-Sevilla, Concepcion Fernández-Rodríguez, Solange Flores, Carmen Raya, Ana Ferrer, Luis Colomo, Antonio Salar

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review-NEW Group (Neutropenic Events Working Group).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ramon Diez-FeijóoDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Juan Jose Rodríguez-SevillaDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Concepcion Fernández-RodríguezDepartment of Pathology, Hospital del Mar, Barcelona, Spain.
Solange FloresDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Carmen RayaBanc de Sang i Teixits, Hospital del Mar, Barcelona, Spain.
Ana FerrerDepartment of Pathology, Hospital del Mar, Barcelona, Spain.
Luis ColomoDepartment of Pathology, Hospital del Mar, Barcelona, Spain.
Antonio SalarDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
Hospital Del Mar · ESBanc de Sang i Teixits · ESHospital del Mar Research Institute · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late onset neutropenia (LON) related to rituximab or rituximab plus chemotherapy is defined as an unexplained absolute neutrophil count of ≤1.5 × 10

Indexed as

AgedAgranulocytosisAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideDose-Response Relationship, DrugHumansImmunoglobulins, IntravenousMaleRituximabTreatment OutcomeWaldenstrom MacroglobulinemiaBendamustine HydrochlorideImmunoglobulins, IntravenousRituximabagranulocytosisbendamustineimmunoglobulinrituximabWaldenström’s macroglobulinemia

Identifiers

PMID35082788
PMCPMC8784545
OpenAlexW4206190800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.